In a move set to reshape the landscape of clinical research technology, Thermo Fisher Scientific Inc. announced Wednesday that it will acquire Clario Holdings Inc. from a consortium led by Astorg, Nordic Capital, Novo Holdings, and Cinven for $8.875 billion in cash. The all-cash acquisition will deepen Thermo Fisher’s foothold in digital clinical trial solutions and expand its artificial intelligence-driven data capabilities.

A Strategic Merger of Science and Software

Clario, a global leader in endpoint data solutions for clinical trials, integrates digital tools to collect, manage, and analyze clinical evidence across every stage of drug development. The company’s platform accelerates how therapies are tested for safety, efficacy, and value—key steps in bringing new medicines to market.

Clario’s expertise spans electronic clinical outcome assessments, medical imaging, cardiac and respiratory monitoring, and wearable data analytics, serving biopharma giants and research organizations across the globe. With around 4,000 employees, Clario is projected to generate $1.25 billion in revenue in 2025.

“A Perfect Strategic Fit,” Says Thermo Fisher CEO

“Clario is an outstanding strategic fit, enabling faster, more informed drug development through differentiated technology and data intelligence,” said Marc N. Casper, Thermo Fisher’s chair, president, and CEO.

Casper added that the acquisition reflects the company’s disciplined capital deployment strategy, which has consistently created shareholder value. By combining Thermo Fisher’s world-class laboratory services with Clario’s advanced data ecosystem, the deal will enhance AI use across clinical trials, boost analytical efficiency, and drive innovation in the biotech and pharmaceutical sectors.

Financial and Legal Details

The transaction—expected to close by mid-2026, pending regulatory approval and customary conditions—will be funded through a mix of debt financing and cash reserves. Thermo Fisher anticipates the deal will deliver a double-digit internal rate of return and be immediately accretive to its adjusted operating margins.

Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment following the close.

WilmerHale is serving as lead deal counsel to Thermo Fisher, with Axinn Veltrop & Harkrider LLP and Freshfields LLP handling regulatory aspects. Latham & Watkins LLP represents Clario and its sellers.

The WilmerHale team is led by partners Hal Leibowitz and Andrew Bonnes. Details on other counsel teams were not immediately available.

Clario’s CEO: “This Partnership Accelerates Our Mission”

“This strategic transaction will power the continued expansion of Clario’s differentiated digital endpoint platform and proprietary suite of AI tools,” said Dr. Chris Fikry, Clario’s CEO. “Thermo Fisher’s global scale and deep ties with large pharma and biotech companies will fuel expansion of our clinical trial platform—benefiting our clients and, ultimately, patients.”

Building the Future of AI-Enabled Medicine

Thermo Fisher, which generates over $40 billion in annual revenue, continues to expand its reach into the biotech and healthcare data sectors. The Clario acquisition is expected to bolster its AI and analytics infrastructure at a pivotal time when pharmaceutical research is becoming increasingly data-driven.

With Thermo Fisher to acquire Clario, the partnership signals not just another corporate merger, but a leap forward in how the world’s most advanced medicines are developed, tested, and delivered—with speed, precision, and digital intelligence at the forefront.